Cipla looking at continued growth across all key markets in FY20

27 May 2019 Evaluate

Cipla is looking at continued growth across all its key markets in the current fiscal year (FY20) and plans to file over 12 abbreviated new drug applications during the period. For the Indian market, it is looking at strong growth in existing franchises including respiratory and ramp-up of chronic therapies such as diabetes, cardio and women health.

For the US market, where the company has seen significant growth driven by ramp-up across key differentiated products in FY19, it is looking to scale-up last fiscal's launches and also introduce more products in FY20 while continuing the specialty investments.

In another key market of South Africa, during the current fiscal year Cipla is looking to strengthen its OTC (over-the-counter) business. In the rest of world market, the company will be focusing on continuing market leadership in key regions.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1406.25 0.85 (0.06%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.